Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents

Keiichi Tsuchida; Andrew T L Ong; Jiro Aoki; Carlos A G van Mieghem; Gastón A Rodriguez-Granillo; Marco Valgimigli; Georgios Sianos; Evelyn Regar; Eugène P McFadden; Willem J van der Giessen; Pim J de Feyter; Peter P T de Jaegere; Ron T van Domburg; Patrick W Serruys

doi:10.1016/j.amjcard.2005.03.084

Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents

Am J Cardiol. 2005 Aug 1;96(3):395-8. doi: 10.1016/j.amjcard.2005.03.084.

Authors

Keiichi Tsuchida¹, Andrew T L Ong, Jiro Aoki, Carlos A G van Mieghem, Gastón A Rodriguez-Granillo, Marco Valgimigli, Georgios Sianos, Evelyn Regar, Eugène P McFadden, Willem J van der Giessen, Pim J de Feyter, Peter P T de Jaegere, Ron T van Domburg, Patrick W Serruys

Affiliation

¹ Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.

PMID: 16054466
DOI: 10.1016/j.amjcard.2005.03.084

Abstract

The aim of this study was to evaluate the outcome after paclitaxel-eluting stent implantation in 40 patients with 52 saphenous vein graft lesions. By Kaplan-Meier estimates, the probability of major adverse cardiac event-free survival for 1 year was 92.5%. A paclitaxel-eluting stent for saphenous vein graft disease appears to be feasible and safe, with a low rate of reintervention at 1 year, but late follow-up is needed to confirm these observations.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Coronary Angiography
Coronary Restenosis / diagnostic imaging
Coronary Restenosis / prevention & control*
Female
Follow-Up Studies
Graft Occlusion, Vascular / diagnostic imaging
Graft Occlusion, Vascular / prevention & control*
Humans
Male
Paclitaxel / administration & dosage*
Prospective Studies
Saphenous Vein*
Stents*
Treatment Outcome

Substances

Paclitaxel